• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Japan·Healthcare·7733.T
Share

Olympus Corporation Stocks

¥ 1720.5Last Updated 12.06.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Low

Recommendation

Hold

Market Cap

¥ 12.37B

¥ 1720.5
Key Takeaways

Risk factor

Strong trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Somewhat favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

29.08.2025 11:42

Goldman and Morgan Stanley differed in their forecasts for Chinese stocks. Is the market already overheated?

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Olympus Corporation, a global enterprise headquartered in Tokyo, Japan, manufactures and distributes high-precision machinery and instrumentation worldwide. The company, originally established in 1919 as Olympus Optical Co., Ltd., adopted its current name in October 2003. Its extensive operations are structured into four primary divisions: Endoscopic Solutions, Therapeutic Solutions, Scientific Solutions, and a segment designated as "Others." The Endoscopic Solutions division specializes in developing and providing gastrointestinal and surgical endoscopes, comprehensive endoscopy systems, and associated repair services. The Therapeutic Solutions segment focuses on products for urology, gynecology, and ear, nose, and throat (ENT) procedures, alongside endo-therapy devices, energy-based surgical tools, and disposable surgical instruments. Within Scientific Solutions, Olympus supplies biological and industrial microscopes, industrial endoscopes and videoscopes, non-destructive testing (NDT) equipment, and X-ray fluorescence (XRF) analyzers. The "Others" segment encompasses biomedical materials and orthopedic equipment. Beyond these core areas, the company also offers a broader array of medical devices, including surgical microscopes, endoscope reprocessing units, electrosurgical tools, and respiratory-endotherapy devices, complemented by system integration and ongoing maintenance services.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA, o

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 7733.T is 1853 and suggests 9% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.06.2026 16:01

Highlights in small-caps: record IPO in biotech, Wizz Air success, SpaceX effect

13.06.2026 13:01

An investment idea for all times, IPO of the year and how to keep emotions in check in the stock market

13.06.2026 03:02

Microsoft is considering spinning off Xbox into a separate company - The Information

13.06.2026 01:40

Hope for peace with Iran and SpaceX lifted spirits: stocks rose for second straight day

13.06.2026 01:05

SpaceX shares rose in value by 19% on the first day of trading. Is it worth buying them?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026